BioSpace News Archive

Graphite Bio, Inc. (Nasdaq: GRPH), a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, today announced the closing of its previously announced initial public offering of 14,000,000 shares of its common stock at a price to the public of $17.00 per share on June 29, 2021.

Rise in cases of chronic and infectious diseases worldwide and increasing volumes of diagnostic tests are expected to propel market growth.

Rising adoption of minimally invasive orthopedic surgery instruments and emergence of cutting-edge technologies including robotic and power-assisted technologies are expected to boost market growth.

Journey Medical Corporation, a partner company of Fortress Biotech, Inc., announced an agreement with Dr. Reddy’s Laboratories Ltd. for the collaborative development and commercialization of the DFD-29 program for the treatment of rosacea.

TRACON Pharmaceuticals announced today the appointment of Ya Huang as Executive Director of Statistical Programming and the grant of an inducement equity award to Mr. Huang.

Histogen Inc. (NASDAQ: HSTO), today announced the initiation of its Phase 1/2 clinical trial of HST 003 to evaluate the safety and efficacy of human extracellular matrix (hECM:HST 003) implanted within microfracture interstices and the cartilage defect in the knee to regenerate hyaline cartilage in combination with a microfracture procedure.

Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that Elizabeth Evans, PhD, Chief Operating Officer and Senior Vice President, Discovery and Translational Medicine, will chair a Symposium and panel Q&A session and present a poster at the XV European Meeting on Glial Cells in Health and Disease,

Sirnaomics, Inc. today announced dose administration for the first patient in a Phase 2b study of the company’s drug candidate, STP705, for the treatment of squamous cell skin cancer in situ (isSCC).

Turner Imaging Systems, a developer of technologically advanced X-ray imaging systems, announced that it has entered a distribution agreement with MIS Healthcare to market its Smart-C fluoroscopic Mini C-Arm in the UK and Ireland.

Alpine Immune Sciences to Collaborate with Merck on Immuno-Oncology Study to Evaluate ALPN-202 in Combination with KEYTRUDA ® (pembrolizumab)